TrialJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2012

A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.

Andrew Weickhardt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.